JP2018529633A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529633A5
JP2018529633A5 JP2018500582A JP2018500582A JP2018529633A5 JP 2018529633 A5 JP2018529633 A5 JP 2018529633A5 JP 2018500582 A JP2018500582 A JP 2018500582A JP 2018500582 A JP2018500582 A JP 2018500582A JP 2018529633 A5 JP2018529633 A5 JP 2018529633A5
Authority
JP
Japan
Prior art keywords
compound
formula
cancer
alkyl
boc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018500582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529633A (ja
JP6917974B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040972 external-priority patent/WO2017007759A1/en
Publication of JP2018529633A publication Critical patent/JP2018529633A/ja
Publication of JP2018529633A5 publication Critical patent/JP2018529633A5/ja
Priority to JP2021069649A priority Critical patent/JP7212713B2/ja
Application granted granted Critical
Publication of JP6917974B2 publication Critical patent/JP6917974B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018500582A 2015-07-06 2016-07-05 ジアリール大環状多形 Active JP6917974B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021069649A JP7212713B2 (ja) 2015-07-06 2021-04-16 ジアリール大環状多形

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562188846P 2015-07-06 2015-07-06
US62/188,846 2015-07-06
US201562218672P 2015-09-15 2015-09-15
US62/218,672 2015-09-15
PCT/US2016/040972 WO2017007759A1 (en) 2015-07-06 2016-07-05 Diaryl macrocycle polymorph

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021069649A Division JP7212713B2 (ja) 2015-07-06 2021-04-16 ジアリール大環状多形

Publications (3)

Publication Number Publication Date
JP2018529633A JP2018529633A (ja) 2018-10-11
JP2018529633A5 true JP2018529633A5 (enExample) 2019-08-15
JP6917974B2 JP6917974B2 (ja) 2021-08-11

Family

ID=57685592

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018500582A Active JP6917974B2 (ja) 2015-07-06 2016-07-05 ジアリール大環状多形
JP2021069649A Active JP7212713B2 (ja) 2015-07-06 2021-04-16 ジアリール大環状多形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021069649A Active JP7212713B2 (ja) 2015-07-06 2021-04-16 ジアリール大環状多形

Country Status (24)

Country Link
US (5) US10294242B2 (enExample)
EP (2) EP4397665A3 (enExample)
JP (2) JP6917974B2 (enExample)
KR (1) KR102623734B1 (enExample)
CN (2) CN113354653B (enExample)
AU (1) AU2016289454B2 (enExample)
BR (1) BR112018000297A2 (enExample)
CA (1) CA2990020C (enExample)
DK (1) DK3319969T3 (enExample)
ES (1) ES2979111T3 (enExample)
FI (1) FI3319969T3 (enExample)
HR (1) HRP20240780T1 (enExample)
HU (1) HUE067352T2 (enExample)
IL (2) IL256443B (enExample)
LT (1) LT3319969T (enExample)
MX (2) MX386680B (enExample)
PL (1) PL3319969T3 (enExample)
PT (1) PT3319969T (enExample)
RS (1) RS65593B1 (enExample)
RU (1) RU2765181C2 (enExample)
SI (1) SI3319969T1 (enExample)
SM (1) SMT202400213T1 (enExample)
WO (1) WO2017007759A1 (enExample)
ZA (1) ZA201708436B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技(苏州)有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
WO2019201131A1 (zh) * 2018-04-16 2019-10-24 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Tyk2阻害剤およびその使用
WO2020233645A1 (zh) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
WO2020257169A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
BR112022010278A2 (pt) 2019-11-27 2022-10-04 Turning Point Therapeutics Inc Terapia combinada que envolve compostos macrocíclicos de diarila
MX2022006366A (es) * 2019-11-27 2022-06-22 Turning Point Therapeutics Inc Terapia de combinacion que implica compuestos de diarilo macrociclico.
EP4114530A4 (en) * 2020-03-02 2024-04-17 Turning Point Therapeutics, Inc. THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS
JP7495035B2 (ja) * 2020-05-08 2024-06-04 シュエンジュウ バイオファーマシューティカル カンパニー リミテッド 大環類チロシンキナーゼ阻害剤の結晶形及びその製造方法
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法
WO2025217347A2 (en) 2024-04-11 2025-10-16 Bristol-Myers Squibb Company Process of preparing repotrectinib

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
EP0281841B1 (de) 1987-03-07 1990-11-14 Bayer Ag Verfahren zur Herstellung von 5-Amino-4,6-dihalogenpyridinen
ATE195935T1 (de) 1993-03-25 2000-09-15 Upjohn Co Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung
PT657458E (pt) 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
GB9403639D0 (en) 1994-02-25 1994-04-13 Boots Co Plc Therapeutic agents
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
JP4180365B2 (ja) 2000-07-31 2008-11-12 エフ.ホフマン−ラ ロシュ アーゲー ピペラジン誘導体
ATE301661T1 (de) 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンh3受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
AU2002322802A1 (en) * 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US8005919B2 (en) 2002-11-18 2011-08-23 Aol Inc. Host-based intelligent results related to a character stream
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
UA91698C2 (ru) * 2005-01-10 2010-08-25 Арена Фармасьютікалз, Інк. Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшенных увеличением уровня glp-1 крови
US8960547B2 (en) 2007-09-19 2015-02-24 E-Seek, Inc. Document scanner with instant retrieval process
US8270176B2 (en) 2008-08-08 2012-09-18 Stats Chippac Ltd. Exposed interconnect for a package on package system
TWM352384U (en) 2008-08-22 2009-03-11 Luff Technology Co Ltd Wireless detection device for club and system thereof
KR20110073500A (ko) * 2008-09-08 2011-06-29 메르크 파텐트 게엠베하 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
WO2011071725A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
WO2011071716A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
ME03376B (me) * 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
GB2482674B (en) 2010-08-09 2012-08-22 Rolls Royce Plc An aerofoil, an aerofoil sub-assembly and a method of making the same
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
EP2541470B1 (en) 2011-06-29 2017-10-04 Denso Wave Incorporated Information code and information code reader
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003802A2 (pt) * 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
WO2013045701A2 (en) 2011-09-29 2013-04-04 L'oreal Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
WO2013045702A2 (en) 2011-09-29 2013-04-04 L'oreal Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JP2016506921A (ja) 2013-01-30 2016-03-07 バイエル ファーマ アクチエンゲゼルシャフト アミノ置換イソチアゾール
WO2014173928A1 (en) 2013-04-23 2014-10-30 Lek Pharmaceuticals D.D. Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
US20150112816A1 (en) * 2013-10-21 2015-04-23 Disney Enterprises, Inc. Systems and methods for providing a graphical user interface for providing brand integration within online content, managing brand integration within online content, and/or managing compensation associated with online content
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
BR202014004079U2 (pt) 2014-02-21 2015-10-27 Mix For You Ltda higienizador íntimo
WO2016070241A1 (en) 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
CA2971024C (en) 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
JP6800158B2 (ja) 2015-02-20 2020-12-16 ライジェル ファーマシューティカルズ, インコーポレイテッド Gdf−8阻害剤
CN107250201B (zh) 2015-03-09 2020-04-28 住友橡胶工业株式会社 轮胎
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
BR112017023764A2 (pt) 2015-05-05 2018-07-31 Bayer Pharma AG derivados de ciclohexano substituído por amido
AU2016287568B2 (en) * 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
US9524416B1 (en) 2015-07-03 2016-12-20 Fingerprint Cards Ab Fingerprint sensing device comprising three-dimensional pattern
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
US10239565B2 (en) 2015-07-17 2019-03-26 John Michael Baker Pickup truck tailgate lifting apparatus
PT3733187T (pt) * 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP6580495B2 (ja) 2016-02-02 2019-09-25 三菱重工業株式会社 保持治具
US11596639B2 (en) 2016-03-04 2023-03-07 Vanderbilt University Substituted indole Mcl-1 inhibitors
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
JP2020533269A (ja) 2016-12-14 2020-11-19 デベロップメント センター フォー バイオテクノロジー 抗体−薬物複合体およびその使用

Similar Documents

Publication Publication Date Title
JP2018529633A5 (enExample)
RU2018104269A (ru) Полиморфная форма диарильного макроцикла
HRP20191944T1 (hr) Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
HRP20171754T1 (hr) Soli i kristalni oblici agensa za induciranje apopotoze
CN104981458B (zh) 组蛋白去甲基化酶抑制剂
CN107304191B (zh) 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
JP2013543894A5 (enExample)
TR201808599T4 (tr) Histon demetilaz inhibitörleri.
ES2394759T3 (es) Pirrolopiridinas como inhibidores de quinasa
HRP20210607T1 (hr) Izokinolin-3-il karboksamidi i njihova priprema i upotreba
JP5684719B2 (ja) Plk阻害剤としての5,7−ジヒドロ−6h−ピリミド[5、−4d][1]ベンゾアゼピン−6−チオン
JP2014514317A5 (enExample)
RU2010121647A (ru) Полиморфы ингибитора c-met/hgfr
ES2780382T3 (es) Derivados de pirazolopirimidina
HRP20161074T1 (hr) Benzoksazolski inhibitori kinaza i postupci njihove upotrebe
JP2010524914A5 (enExample)
RU2012115851A (ru) Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2
RU2016108667A (ru) Комбинированная терапия для лечения рака
JP2010518110A5 (enExample)
CN103998450A (zh) 吡咯并苯并二氮杂卓
JP2024514847A5 (enExample)
ES2392014T3 (es) Pirazolopiridinas como inhibidores de la cinasa
RU2009122242A (ru) Кристаллические формы сольватированного илапразола
JP2021519262A5 (enExample)
JP2020505333A (ja) Nhe媒介性アンチポートの阻害薬